{"id":997618,"date":"2026-08-24T14:53:37","date_gmt":"2026-08-24T18:53:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/"},"modified":"2026-08-24T14:53:37","modified_gmt":"2026-08-24T18:53:37","slug":"shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/","title":{"rendered":"Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately"},"content":{"rendered":"<h2>\nLead Plaintiff Deadline October 13, 2026<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK and SAN DIEGO, Aug.  24, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5Bd0MQ3pXNFgqTj9qn6GcBvtqh7gRfGMpAh0gbQDaogow2X_Nvy0Y4hQgzEoMXJ5A5E3zI3xbZQGPnOfp2MlMAqNnSZdSlTUmwL2MfhjieWgDnefcJzJagw16SQv8f_j86pAKr3XmFucUtDsAZXLd4jTdg9bgaPsP14BooMBcUBcLSYAnf2Madn6lkrpe20vwNPakC9fjtSUjy5DFI8Y3A==\" rel=\"nofollow\" target=\"_blank\">Wolf Haldenstein Adler Freeman &amp; Herz LLP (\u201cWolf Haldenstein\u201d),<\/a> a nationally recognized securities litigation law firm, announces that a securities class action lawsuit has been filed in the announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (\u201cAardvark\u201d or the \u201cCompany\u201d):<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt;text-align:justify\">common stock pursuant and\/or traceable to the Offering Documents issued in connection with the Company\u2019s Initial Public Offering (the \u201cIPO\u201d or \u201cOffering\u201d) conducted on or about February 13, 2025 and\/or<\/li>\n<li style=\"margin-bottom:8pt;text-align:justify\">Aardvark securities between February 13, 2025, and May 14, 2026, both dates inclusive (the \u201cClass Period\u201d).\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Investors who purchased Aadvark shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for October 13, 2026.<\/strong>\n      <\/p>\n<p align=\"justify\">The filed Complaint alleges that Defendants failed to disclose to investors that:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt;text-align:justify\">ARD-101 was less safe than Defendants had led investors to believe;<\/li>\n<li style=\"margin-bottom:8pt;text-align:justify\">accordingly, ARD-101\u2019s clinical, regulatory, and commercial prospects were<br \/>overstated; and<\/li>\n<li style=\"margin-bottom:8pt;text-align:justify\">as a result, Defendants\u2019 public statements were materially false and misleading at all relevant times.\n<\/li>\n<\/ul>\n<p align=\"justify\">It is alleged that the truth began to emerge on February 27, 2026, when Aardvark issued a press release <em>\u201cannounc[ing] it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial.\u201d<\/em> Aardvark attributed the decision to <em>\u201creversible cardiac observations at above target therapeutic doses found during routine safety monitoring in a healthy volunteer study\u201d <\/em>and said that it<em> \u201chas voluntarily paused ongoing enrollment and dosing in the HERO trial\u201d<\/em> while <em>\u201cconducting a comprehensive review of the data to inform next steps.\u201d<\/em><\/p>\n<p>On this news, Aardvark\u2019s stock price fell $7.02 per share, or 56.2%, to close at $5.47 per share on March 2, 2026.<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5TDfC8LaxNWp_0yefPRDPMCMYe8SgaLur9G98GMaArBv-_Znrg3u-na_7hXzkZM13uawMVDcqEBn7kMajyHEp9ZHKufWGaK3q4fzf66SlrG-GdFenwF7BIcEyVZ8CEyyHpui4AVebF89dUdst0LYMw==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>WHY WOLF HALDENSTEIN?<\/strong><br \/>\n        <\/a>\n      <\/p>\n<p align=\"justify\">This illustrious<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CJ0sNq6_2YCxwTwPxDPZ9CshnSI5R0m1UkIoqx1hSNTIQ-J7m45BRM92qRN5u1_PiN5Lkrulf6b_KM5fmdwtUdMJKd4QqFIhHjP2ok80NIEvpWAzjxAF84-0PBPc6IZl\" rel=\"nofollow\" target=\"_blank\"> firm,<\/a> founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements.\u00a0The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KE6V-nkX4vySz7FrHBHAsF0EO8fWvQI6KDttJjQ4uLPpV_1O5xdly2xeQu8jXB5-YSvwJATf2bFImBF7L8K_Z1tWYtrFAq5241djhghXMHUpmpW3Sf-4S5bRTBrfmWk7\" rel=\"nofollow\" target=\"_blank\">law firm\u00a0<\/a>brings to the fore over 125 years of legal expertise in securities litigation and has a proven record of protecting the rights of investors.<\/p>\n<p align=\"justify\">We encourage all investors who have been affected or have information that will assist in our investigation, to contact\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5Bd0MQ3pXNFgqTj9qn6GcBvtqh7gRfGMpAh0gbQDaogow2X_Nvy0Y4hQgzEoMXJ5zOQc8oImuw6keeA6YHijGsz0W5ApyB87BgrxMNc3rSDsFs_0RttQkAyIVp0Ux92YQbeJLDFMgQLYOcQDp0TVqf5-Bt_JmE9aDuJovkuLwpY=\" rel=\"nofollow\" target=\"_blank\">Wolf Haldenstein Adler Freeman &amp; Herz LLP.<\/a><\/p>\n<p>\n        <br \/>\n        <strong>There is no cost or obligation to speak with an attorney.<\/strong><br \/>\n        \n      <\/p>\n<p>\n        <strong>Contact:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Phone:<\/strong>\u00a0(800) 575-0735 or (212) 545-4774<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Email:\u00a0<\/strong><br \/>\n          <a href=\"mailto:classmember@whafh.com\" rel=\"nofollow\" target=\"_blank\">classmember@whafh.com<\/a>\n        <\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Contact Person:<\/strong>\u00a0<a href=\"mailto:gstone@whafh.com\" rel=\"nofollow\" target=\"_blank\">Gregory Stone, Director of Case and Financial Analysis<\/a><\/p>\n<\/li>\n<\/ul>\n<p>\n        <strong>Firm Website:<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=95L_DQn7GRkW3z6kp4csvElroG6PSn6qugPyqOI-Uj2gqEabx6wfdabHEh8PbbjUi0LqIaGtjrWDcxK1HinK2GSyV-tdipTKLC88UpvaggLitp4mV3VXk2uavj7zoEOs-Kh93C6QmlS86UtJM1vhwoiEU4QcblUVQsM_nU2tI48=\" rel=\"nofollow\" target=\"_blank\">\u00a0Wolf Haldenstein Adler Freeman &amp; Herz LLP<\/a>\n      <\/p>\n<p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTExMCM3ODAwNzU1IzIwMTc2NzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjVkOTljMTQtOGZkYy00YWE2LWJmNzAtZmU2OTQyMDk1ZDM3LTEwMjkyNDItMjAyNi0wOC0yNC1lbg==\/tiny\/Wolf-Haldenstein-Adler-Freeman.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lead Plaintiff Deadline October 13, 2026 NEW YORK and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) &#8212; Wolf Haldenstein Adler Freeman &amp; Herz LLP (\u201cWolf Haldenstein\u201d), a nationally recognized securities litigation law firm, announces that a securities class action lawsuit has been filed in the announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (\u201cAardvark\u201d or the \u201cCompany\u201d): common stock pursuant and\/or traceable to the Offering Documents issued in connection with the Company\u2019s Initial Public Offering (the \u201cIPO\u201d or \u201cOffering\u201d) conducted on or about February 13, 2025 and\/or Aardvark securities &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-997618","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Lead Plaintiff Deadline October 13, 2026 NEW YORK and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) &#8212; Wolf Haldenstein Adler Freeman &amp; Herz LLP (\u201cWolf Haldenstein\u201d), a nationally recognized securities litigation law firm, announces that a securities class action lawsuit has been filed in the announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (\u201cAardvark\u201d or the \u201cCompany\u201d): common stock pursuant and\/or traceable to the Offering Documents issued in connection with the Company\u2019s Initial Public Offering (the \u201cIPO\u201d or \u201cOffering\u201d) conducted on or about February 13, 2025 and\/or Aardvark securities &hellip; Continue reading &quot;Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-24T18:53:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTExMCM3ODAwNzU1IzIwMTc2NzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately\",\"datePublished\":\"2026-08-24T18:53:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\\\/\"},\"wordCount\":456,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNTExMCM3ODAwNzU1IzIwMTc2NzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\\\/\",\"name\":\"Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNTExMCM3ODAwNzU1IzIwMTc2NzI=\",\"datePublished\":\"2026-08-24T18:53:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNTExMCM3ODAwNzU1IzIwMTc2NzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNTExMCM3ODAwNzU1IzIwMTc2NzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/","og_locale":"en_US","og_type":"article","og_title":"Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately - Market Newsdesk","og_description":"Lead Plaintiff Deadline October 13, 2026 NEW YORK and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) &#8212; Wolf Haldenstein Adler Freeman &amp; Herz LLP (\u201cWolf Haldenstein\u201d), a nationally recognized securities litigation law firm, announces that a securities class action lawsuit has been filed in the announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (\u201cAardvark\u201d or the \u201cCompany\u201d): common stock pursuant and\/or traceable to the Offering Documents issued in connection with the Company\u2019s Initial Public Offering (the \u201cIPO\u201d or \u201cOffering\u201d) conducted on or about February 13, 2025 and\/or Aardvark securities &hellip; Continue reading \"Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-24T18:53:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTExMCM3ODAwNzU1IzIwMTc2NzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately","datePublished":"2026-08-24T18:53:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/"},"wordCount":456,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTExMCM3ODAwNzU1IzIwMTc2NzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/","name":"Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTExMCM3ODAwNzU1IzIwMTc2NzI=","datePublished":"2026-08-24T18:53:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTExMCM3ODAwNzU1IzIwMTc2NzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTExMCM3ODAwNzU1IzIwMTc2NzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-acquired-aardvark-therapeutics-inc-nasdaq-aard-should-contact-wolf-haldenstein-immediately\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/997618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=997618"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/997618\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=997618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=997618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=997618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}